170 related articles for article (PubMed ID: 30499247)
1. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.
Takeda H; Nishijima N; Nasu A; Komekado H; Kita R; Kimura T; Kudo M; Osaki Y
Hepatol Res; 2019 May; 49(5):594-599. PubMed ID: 30499247
[TBL] [Abstract][Full Text] [Related]
2. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
[TBL] [Abstract][Full Text] [Related]
3. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.
Ohya Y; Hayashida S; Tsuji A; Kuramoto K; Shibata H; Setoyama H; Hayashi H; Kuriwaki K; Sasaki M; Iizaka M; Nakahara O; Inomata Y
Surg Case Rep; 2020 Dec; 6(1):318. PubMed ID: 33301055
[TBL] [Abstract][Full Text] [Related]
4. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.
Endo K; Kuroda H; Abe T; Sato H; Kooka Y; Oikawa T; Sato A; Nishiya M; Sugai T; Takikawa Y
Hepatol Res; 2021 Oct; 51(10):1082-1086. PubMed ID: 33982336
[TBL] [Abstract][Full Text] [Related]
5. Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report.
Miwa T; Kochi T; Watanabe K; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Katsumura N; Shimizu M
J Rural Med; 2021 Apr; 16(2):102-110. PubMed ID: 33833836
[No Abstract] [Full Text] [Related]
6. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
7. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports.
Komiyama S; Numata K; Moriya S; Fukuda H; Chuma M; Maeda S
World J Clin Cases; 2020 Jun; 8(12):2574-2584. PubMed ID: 32607334
[TBL] [Abstract][Full Text] [Related]
9. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
10. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature.
Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Morishita A; Kobara H; Masaki T
Mol Clin Oncol; 2021 Aug; 15(2):154. PubMed ID: 34178325
[TBL] [Abstract][Full Text] [Related]
11. A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib.
Osuga T; Miyanishi K; Ito R; Tanaka S; Hamaguchi K; Ohnuma H; Murase K; Takada K; Nagayama M; Kimura Y; Sugawara T; Sugita S; Takemasa I; Hasegawa T; Kato J
Case Rep Oncol; 2022; 15(1):318-325. PubMed ID: 35529291
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.
Morsica G; Bertoni C; Hasson H; Messina E; Uberti Foppa C
Front Oncol; 2023; 13():1242741. PubMed ID: 38115904
[TBL] [Abstract][Full Text] [Related]
13. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
14. Hepatic encephalopathy induced by Lenvatinib and anti-PD-1 mAb in a patient with advanced hepatocellular carcinoma: A case report.
Liu Z; Meng Y; Xiao W; Wang H; Sun L; Fu Z; Xiong X; Zhang S
Mol Clin Oncol; 2021 Jun; 14(6):110. PubMed ID: 33859824
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Sho T; Suda G; Ogawa K; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Baba M; Ito J; Yamamoto Y; Kobayashi T; Meguro T; Saga A; Miyagishima T; Terasita K; Takagi T; Kamiyama T; Taketomi A; Sakamoto N
Hepatol Res; 2020 Aug; 50(8):966-977. PubMed ID: 32562334
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report.
Endo Y; Shimazu M; Sakuragawa T; Uchi Y; Edanami M; Sunamura K; Ozawa S; Chiba N; Kawachi S
World J Gastrointest Surg; 2022 Mar; 14(3):260-267. PubMed ID: 35432767
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy.
Shintani H; Oura S; Makimoto S
Case Rep Oncol; 2021; 14(2):772-777. PubMed ID: 34177529
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Kasuya K; Sano T; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Liver Cancer; 2020 Jun; 9(3):275-292. PubMed ID: 32647631
[TBL] [Abstract][Full Text] [Related]
20. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
